💊 Chronic Pain Non-Opioid Switch Deprescribing Simulator

Chronic Opioid Therapy — Tolerance and Dependence

Years of steady dosing have reshaped receptors, raising tolerance and physical dependence.

• 90 MME: Baseline dose (morphine milligram equivalents/day)
• 3+ yrs: Therapy duration (typical long-term regimen)
• ~40%: Receptor downregulation (mu-receptor density loss)
• ~85%: Pain control (reported at baseline dose)

Tolerance develops with repeated exposure

Receptors desensitize, so the same dose controls less pain over time.

Physical dependence is not addiction

The body adapts physiologically, distinct from compulsive misuse behavior.

Deprescribing candidacy is assessed first

Function, risk factors, and pain trajectory guide the taper decision.

Non-Opioid Agent Introduced Alongside Opioid

A non-opioid analgesic is layered in before any opioid dose reduction begins.

• SNRI/Gabapentinoid: Agent class (or topical/NSAID combination)
• 2–4 wks: Onset to effect (gradual analgesic ramp-up)
• ~25%: Starting share (of total pain control)
• Unchanged: Opioid dose (held steady during titration)

Overlap avoids a pain-control gap

New agent builds efficacy before opioid dose ever drops.

Agent choice matches the pain mechanism

Neuropathic, nociceptive, or mixed pain drives drug selection.

Side-effect tolerability is checked early

Dose is titrated slowly to confirm the patient tolerates it.

Gradual Opioid Taper Begins

Opioid dose is lowered in small scheduled steps while non-opioid coverage grows.

• 5–10%: Taper rate (dose reduction per interval)
• 1–2 wks: Review interval (reassessment between steps)
• >15%: Withdrawal onset (cut triggers symptom risk)
• ~55%: Non-opioid share (of pain control by this point)

Slower cuts reduce withdrawal symptoms

Small, spaced reductions keep the body adapting comfortably.

Faster tapers raise symptom and dropout risk

Aggressive pace increases withdrawal signs and pain flares.

Monitoring catches problems before they escalate

Pain scores and withdrawal signs are tracked at each step.

Pace can be slowed or paused anytime

Taper plans stay flexible around patient response, not fixed.

Overlap Period — Non-Opioid Takes The Lead

Non-opioid coverage now exceeds opioid coverage as the taper advances further.

• ~week 5–6: Crossover point (non-opioid overtakes opioid)
• ~25%: Opioid remaining (of original baseline dose)
• ~85%: Non-opioid dose (of full maintenance target)
• Pace-dependent: Pain variance (stable if slow, dips if fast)

Pain control stability depends on pace

Slow and moderate tapers keep pain scores essentially flat.

Fast tapers can cause a temporary dip

Rapid cuts outrun the non-opioid agent's compensating effect.

Withdrawal risk peaks during this crossover window

Symptom risk is highest right where doses cross over.

Opioid Discontinued — Non-Opioid Maintenance

The opioid is fully stopped while the non-opioid analgesic sustains pain control.

• 0%: Opioid dose (fully discontinued)
• ~80–85%: Long-term pain control (maintained on non-opioid alone)
• <15%: Relapse rate (with slow, monitored tapers)
• Weeks–months: Receptor recovery (mu-receptor density normalizes)

Non-opioid therapy now stands alone

The analgesic fully replaces opioid coverage going forward.

Follow-up prevents silent relapse into opioid use

Scheduled check-ins catch pain flares before opioids restart.

Slow tapers show the best long-term outcomes

Gradual pacing correlates with lower relapse and withdrawal rates.